Seasonal affective disorder (SAD) is a mood disorder subset in which people who have normal mental health throughout most of the year exhibit depressive symptoms at the same time each year, most commonly in the winter. Common symptoms include sleeping too much, having little to no energy, and overeating. The condition in the summer can include heightened anxiety.Report OverviewDue to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Seasonal Affective Disorder Therapeutics estimated at USD million in the year 2022, is projected to reach a revised size of USD million by 2028, growing at a CAGR of percent during the forecast period 2022-2028.The USA market for Seasonal Affective Disorder Therapeutics is estimated to increase from USD million in 2022 to reach USD million by 2028, at a CAGR of percent during the forecast period of 2023 through 2028.The China market for Seasonal Affective Disorder Therapeutics is estimated to increase from USD million in 2022 to reach USD million by 2028, at a CAGR of percent during the forecast period of 2023 through 2028.The Europe market for Seasonal Affective Disorder Therapeutics is estimated to increase from USD million in 2022 to reach USD million by 2028, at a CAGR of percent during the forecast period of 2023 through 2028.The global key companies of Seasonal Affective Disorder Therapeutics include Allergan, Pfizer, Roche, Eli Lily, GlaxoSmithKline, Teva Pharmaceuticals, Bausch Health Companies, Mylan and Sanofi, etc. In 2021, the global top five players had a share approximately percent in terms of revenue.